March 26, 2018 04:36 AM EDT
R&D

Beat­ing out mar­ket lead­ers in PhII, an­tibi­ot­ic-mak­er Al­le­cra read­ies for Phase III tri­als

Brittany Meiling

Eu­ro­pean biotech Al­le­cra an­nounced good news from the front­lines of its fight against mul­tidrug-re­sis­tant gram-neg­a­tive bac­te­ria – some of the most dan­ger­ous su­per­bugs around …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

Califf, on his way out at FDA, pre­dicts agency tug-of-war be­tween Ra­maswamy and RFK Jr.

A service from the Financial Times